Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 701–800 of 1,000
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
“This suggests that the CTLA-4 blockade mostly exerts its anti-cancer activity by suppressing this inhibitory CD4+ T cell population [21,22].”
Li, Q., Cao, M., Yuan, G., Cheng, X., Zang, M., Chen, M., Hu, X., Huang, J., Li, R., Guo, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809709 · Cited by 37
Combined nano cancer immunotherapy based on immune status in a tumor microenvironment
Nakamura, T., Kawakami, K., Nomura, M., Sato, Y., Hyodo, M., Hatakeyama, H., Hayakawa, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.026 · Cited by 34
Hussain, K., Liu, R., Smith, R. C. G., Müller, K. T. J., Ghorbani, M., Macari, S. A., Cleary, K. L. S., Oldham, R. J., Foxall, R. B., James, S., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02294-5 · Cited by 36
Combinations of radiotherapy with immunotherapy in cervical cancer
Yang, X., Ren, H., & Fu, J. (2022) · Journal of Cancer · doi:10.7150/jca.65074 · Cited by 34
“The authors proposed that OX-40 functions by increasing antigen-specific T cell numbers, while anti-CTLA-4 acts as a down-regulator of regulatory T cells [63].”
BackgroundSeremet, T., Koch, A., Jansen, Y. J. L., Schreuer, M. S., Wilgenhof, S., del Mármol, V., Líénard, D., Thielemans, K., Schats, K., Kockx, M. M., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0990-x · Cited by 33
“repertoire has been documented [4], and in animal models anti-CTLA-4 therapy was shown to deplete tumor-associated regulatory T cells [5].”
Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells
Do, P., Beckwith, K. A., Cheney, C. M., Tran, M., Beaver, L. P., Griffin, B. G., Mo, X. M., Liu, Y., Lapalombella, R., Hertlein, E. K., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801359 · Cited by 33
Dougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 36
New Strategies in Melanoma: Entering the Era of Combinatorial Therapy
Sullivan, R. J., & Flaherty, K. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1650 · Cited by 36
“More recently, it also appears that intratumoral depletion of regulatory T cells is another potential mechanismof action of anti–CTLA-4 treatment (37).”
BackgroundCytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma
Buchbinder, E. I., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.003 · Cited by 33
Targeting regulatory T cells in tumor immunotherapy
Smyth, M. J., Ngiow, S. F., & Teng, M. W. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.33 · Cited by 32
Lotem, M., Merims, S., Frank, S. J., Hamburger, T., Nissan, A., Kadouri, L., Cohen, J. E., Straussman, R., Eisenberg, G., Frankenburg, S., et al. (2016) · Journal of Immunology Research · doi:10.1155/2016/8121985 · Cited by 32
“CTLA-4 receptor blockade prevents inhibition of activated effector lymphocytes and selective increase in the ratio between T effectors and regulatory T cells within the tumor [52].”
Cari, L., Nocentini, G., Migliorati, G., & Riccardi, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1387705 · Cited by 32
“, it involves tumor-infiltrating Tregs more than Tregs outside the tumor) and, thus, favors the killing of Tregs directed against tumor antigens.(7,9,10,57,58) ADCC is specifically targeted against tumors because it requires the expression of activating FcgRs, which are not expressed by cells in the lymph nodes or oth…”
BackgroundInfluentialAn Immune-Stimulatory Helix–Loop–Helix Peptide: Selective Inhibition of CTLA-4–B7 Interaction
Mudiyanselage, T. M. R. R., Michigami, M., Ye, Z., Uyeda, A., Inoue, N., Sugiura, K., Fujii, I., & Fujiwara, D. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00743 · Cited by 32
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis
Li, Y., Wang, Z., Lin, H., Wang, L., Chen, X., Liu, Q., Zuo, Q., Hu, J., Wang, H., Guo, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00806 · Cited by 32
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
Okura, N., Asano, M., Uchino, J., Morimoto, Y., Iwasaku, M., Kaneko, Y., Yamada, T., Fukui, M., & Takayama, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072033 · Cited by 33
Regulatory T Cells in the Tumor Microenvironment
Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 34
Kanda, Y., Okazaki, T., & Katakai, T. (2021) · Cancers · doi:10.3390/cancers13184616 · Cited by 36
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 37
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Rossi, A., Belmonte, B., Carnevale, S., Liotti, A., Rosa, V. D., Jaillon, S., Piconese, S., & Tripodo, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.933113 · Cited by 36
Moran, A. E., Polesso, F., & Weinberg, A. D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502659 · Cited by 34
“Given that anti-CTLA4 therapy has been shown to deplete tumorassociated Tregs in mice (62), the increase in CD8GFP T cells with this therapy might reflect a reinvigoration of memory CD8 T cells, some of which have high-affinity TCRs.”
BackgroundGoletz, C., Lischke, T., Harnack, U., Schiele, P., Danielczyk, A., Rühmann, J., & Goletz, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01614 · Cited by 32
“Similar observations were reported for anti-CTLA-4, anti-GITR, and anti-OX40 antibodies in murine systems demonstrating that binding to activating FcγR results in depletion of intra-tumoral Tregs and contributes to anti-tumor activity (30, 38–40).”
BackgroundInfluentialIn situ antitumor vaccination: Targeting the tumor microenvironment
Li, H., Yu, J., Wu, Y., Shao, B., & Wei, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29551 · Cited by 35
“Furthermore, recent data manifested that the in vivo efficacy of antagonistic anti‐CTLA‐4 therapy was mediated via selective depletion of Treg cells within tumor lesions (Marabelle et al., 2013; Simpson et al., 2013).”
BackgroundRecent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
“5–2-fold increase in T-cell proliferation, enhanced IL-2 production [127], and depleted Treg in the tumor microenvironment [128].”
BackgroundAnti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
Mok, S., Liu, H., Çobanoğlu, D. A., Anang, N.-A. A. S., Mancuso, J. J., Wherry, E. J., & Allison, J. P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418985122 · Cited by 33
“In contrast, another anti - CTLA - 4 antibody (clone 9D9) or anti - PD - 1 antibodies do not have a Fc chain that supports antibody - dependent cellular cytotoxicity (ADCC) for Treg depletion ( 22 , 23 ).”
Self-citationCancer immunology – development of novel anti-cancer therapies
Rothschild, S. I., Thommen, D. S., Moersig, W., Müller, P., & Zippelius, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14066 · Cited by 33
Recent developments and future challenges in immune checkpoint inhibitory cancer treatment
Koster, B. D., de Gruijl, T. D., & van den Eertwegh, A. J. M. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000221 · Cited by 31
Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?
Liu, W., Almo, S. C., & Zang, X. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1186690 · Cited by 34
“Two other studies also indicated Fc-γ-dependent elimination of Tregs improved the efficacy of anti-CTLA-4 mAbs–mediated antitumor immunity in mice (Bulliard et al., 2013; Simpson et al., 2013).”
BackgroundGarp as a therapeutic target for modulation of T regulatory cell function
Shevach, E. M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1275568 · Cited by 33
“lization and potentiation of Treg suppressor function [63].”
BackgroundRadiotherapy as a New Player in Immuno-Oncology
Wang, S.-J., & Haffty, B. G. (2018) · Cancers · doi:10.3390/cancers10120515 · Cited by 31
“These findings are consistent with known mechanisms of CTLA-4 and OX40 therapies; CTLA-4 inhibition can deplete intratumoral Tregs prior to radiotherapy to mitigate the immunosuppressive TME and enhance immunogenicity of radiation, while OX40 co-stimulatory molecules are upregulated only for a brief period after antig…”
ResultCTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro
Rosskopf, S., Leitner, J. M., Zlabinger, G. J., & Steinberger, P. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02369-x · Cited by 35
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
Qu, Q., Zhai, Z., Xu, J., Li, S., Chen, C., & Lu, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00634 · Cited by 31
Gamat, M., Jeon, D., Johnson, L. E., Moseman, J. E., Muralidhar, A., Potluri, H. K., Rastogi, I., Wargowski, E., Zahm, C. D., & McNeel, D. G. (2020) · Cancers · doi:10.3390/cancers12102831 · Cited by 32
“Finally, a pilot phase 1 study (NCT03532217) is recruiting patients with metastatic castration-sensitive prostate cancer to investigate the effects of PROSTVAC in combination with a DNA vaccine encoding patient-specific neoantigens and checkpoint blockade (anti-CTLA-4 plus anti-PD-1).”
BackgroundInfluentialIsotype selection for antibody-based cancer therapy
Vukovic, N., van Elsas, A., Verbeek, J. S., & Zaiss, D. M. W. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13545 · Cited by 33
Domain binding and isotype dictate the activity of anti-human OX40 antibodies
Griffiths, J., Hussain, K., Smith, H. L., Sanders, T. J., Cox, K. L., Semmrich, M., Mårtensson, L., Kim, J., Inzhelevskaya, T., Penfold, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001557 · Cited by 31
Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics
Du, Y., Fang, Q., & Zheng, S. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_1 · Cited by 34
Davis-Marcisak, E. F., Fitzgerald, A. A., Kessler, M. D., Danilova, L., Jaffee, E. M., Zaidi, N., Weiner, L. M., & Fertig, E. J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00944-5 · Cited by 34
Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity
Kamphorst, A. O., Araki, K., & Ahmed, R. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.082 · Cited by 34
Zhang, Z., Bao, C., Jiang, L., Wang, S., Wang, K., Lu, C., & Fang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054233 · Cited by 38
Lee, H., Ferguson, A. L., Quek, C. Y. J., Vergara, I. A., da Silva, I. P., Allen, R. O., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2657 · Cited by 32
Wong, R. S. J., Ong, R. J. M., & Lim, J. S. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.58 · Cited by 31
Roider, H. G., Hoff, S., Tseng, S.-Y., Berndt, S., Trautwein, M., Filarsky, K., Gritzan, U., Camps, J., Nadler, W. M., Grudzinska‐Goebel, J., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01362-8 · Cited by 32
“…of how CCR8+ Tregs are eliminated from tumors and is consistent with findings from other Treg-targeting approaches, such as anti-CTLA-4 antibodies, where it has been shown in mice that Treg depletion rather than functional blockade was necessary, with ADCP being the key effector mechanism [27, 28].”
BackgroundResultKeshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 31
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
Burn, O. K., Prasit, K., & Hermans, I. F. (2020) · Cancers · doi:10.3390/cancers12123824 · Cited by 31
“Interestingly, in this combination setting, there was an increase in Fcγ receptor IV expression on macrophages, resulting in greater antibody-dependent macrophage-mediated depletion of CTLA-4-positive Tregs in the tumour [33,117].”
BackgroundIFN-γ and CD38 in Hyperprogressive Cancer Development
Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 34
Schofield, D. J., Percival‐Alwyn, J., Rytelewski, M., Hood, J., Rothstein, R. P., Wetzel, L. K., McGlinchey, K., Adjei, G., Watkins, A., Machiesky, L., et al. (2021) · mAbs · doi:10.1080/19420862.2020.1857100 · Cited by 30
“These findings led to the hypothesis that the anti-tumor activity of anti–CTLA-4 mAbs is dependent on effector function.(18,33,34) However, the relevance of Treg depletion for the clinical activity of ipilimumab and tremelimumab has been called into question because a lack of intratumoral Treg depletion has been obser…”
BackgroundImmune Checkpoint Blockade and Skin Toxicity Pathogenesis
Ma, B., & Anandasabapathy, N. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.040 · Cited by 34
Habib, S., Osborn, G., Willsmore, Z. N., Chew, M. W., Jakubow, S., Fitzpatrick, A., Wu, Y., Sinha, K., Lloyd-Hughes, H., Geh, J. L. C., et al. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2326626 · Cited by 34
“…Fab portion of Ipilimumab binding and preventing the regulatory action of CTLA-4 on T cells, Tregs expressing high levels of CTLA-4 could be targeted by ipilimumab with the Fc portion of the antibody binding FcγRs expressed on immune cells including macrophages, inducing ADCC of Tregs [101,102].”
BackgroundRudolph, B. M., Staib, F., von Stebut, E., Hainz, M., Grabbe, S., & Loquai, C. (2014) · European Journal of Dermatology · doi:10.1684/ejd.2014.2297 · Cited by 31
“Only seven cases have been accepted as unequivocal adenocarcinoma of Moll’s gland [3-8].”
Gordan, S., Biburger, M., & Nimmerjahn, F. (2015) · Immunological Reviews · doi:10.1111/imr.12347 · Cited by 37
“With respect to the therapeutic outcome, mice deficient in FccRs were no longer protected by CTLA4-Fc fusion proteins from tumor growth, suggesting that macrophage-mediated depletion of Tregs is a major component of the therapeutic activity of checkpoint control antibodies or Fc-fusion proteins (76).”
BackgroundRadiation Therapy and Immunotherapy: Growing Pains
Golden, E. B., & Formenti, S. C. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.018 · Cited by 30
Decoding the potential role of regulatory T cells in sepsis‐induced immunosuppression
Huang, S., Liu, D., Han, L., Deng, J., Wang, Z., Jiang, J., & Zeng, L. (2024) · European Journal of Immunology · doi:10.1002/eji.202350730 · Cited by 30
Lu, Y., Houson, H. A., Gallegos, C., Mascioni, A., Jia, F., Aivazian, A., Song, P. N., Lynch, S. E., Napier, T. S., Mansur, A., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01844-3 · Cited by 33
“Furthermore, α-CTLA4 impacts the tumor microenvironment in at least two different ways: (1) by depleting regulatory T-cells via antibody-dependent cellular cytotoxicity (ADCC) [33] or by disturbed glycolysis [34]; (2) by activating T helper populations [9, 35].”
BackgroundFc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology
Martineau, R., Susini, S., & Marabelle, A. (2024) · Immunological Reviews · doi:10.1111/imr.13427 · Cited by 33
Yi, G., Guo, S., Liu, W., Wang, H., Liu, R., Tsun, A., Jin, G. Y., & Li, B. (2018) · 中国科学通报:英文版 · doi:10.1016/j.scib.2018.05.028 · Cited by 31
Alimohammadi, R., Alibeigi, R., Nikpoor, A. R., Chalbatani, G. M., Webster, T. J., Jaafari, M. R., & Jalali, S. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s260760 · Cited by 30
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
Sato, Y., Casson, C. N., Matsuda, A., Kim, J. I., Shi, J. Q., Iwasaki, S., Chen, S. E., Modrell, B., Chan, C., Tavares, D., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03170-z · Cited by 29
“Collectively, these data suggested that selective FcγR-mediated intratumoral Treg depletion was a driver in promoting anti-CTLA-4 antibodymediated anti-tumor activity [12, 13].”
BackgroundExploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29
Advances in the study of CD47 ‐based bispecific antibody in cancer immunotherapy
Zhang, B., Li, W., Fan, D., Tian, W., Zhou, J., Ji, Z., & Song, Y. (2022) · Immunology · doi:10.1111/imm.13498 · Cited by 32
Shen, H., Huang, F., Zhang, X., Ojo, O. A., Li, Y., Trummell, H. Q., Anderson, J. C., Fiveash, J. B., Bredel, M., Yang, E. S.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32754-7 · Cited by 30
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
Adams, R., Osborn, G., Mukhia, B., Laddach, R., Willsmore, Z. N., Chenoweth, A. M., Geh, J. L. C., Ross, A. D. M., Healy, C., Barber, L. D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2127284 · Cited by 31
“of human FcγRIIIA (see Table 1), are associated with antibodymediated lysis of Treg cells.(82) These studies demonstrate the interplay of different immune cells within the TME and the importance of taking into consideration the interactions between antibody Fc regions and immune cells such as macrophages when designin…”
BackgroundSelective activation of anti-CD73 mechanisms in control of primary tumors and metastases
Vijayan, D., Barkauskas, D. S., Stannard, K. A., Sult, E., Buonpane, R. A., Takeda, K., Teng, M. W. L., Sachsenmeier, K. F., Hay, C. M., & Smyth, M. J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1312044 · Cited by 32
Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 29
“Some studies also showed that the depletion of Tregs during ICI treatment may be associated with ICI efficacy.(51,52) Although some studies showed that eradicating or reprogramming other immunosuppressive factors, such as myeloid-derived suppressor cells (MDSCs), γδT cells, and macrophages, could enhance clinical resp…”
Strategies for Predicting Response to Checkpoint Inhibitors
Zappasodi, R., Wolchok, J. D., & Merghoub, T. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0471-9 · Cited by 30
Self-citationLi, B., Li, T., Liu, J. S., & Liu, X. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0327-7_18 · Cited by 29
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 30
Bardoscia, L., Pasinetti, N., Triggiani, L., Cozzi, S., & Sardaro, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.746853 · Cited by 30
“Alongside the improved synergistic efficacy, reduced antitumor effects have been described in cases of ICIs plus RT administration for the treatment of large tumors (Eckert et al., 2018), together with preclinical evidence of conventional normofractionation to possibly have anti-immunogenic properties through the indu…”
BackgroundInfluentialBaltussen, J. C., Welters, M. J. P., Verdegaal, E. M. E., Kapiteijn, E., Schrader, A. M. R., Slingerland, M., Liefers, G., van der Burg, S. H., Portielje, J. E. A., & de Glas, N. A. (2021) · Cancers · doi:10.3390/cancers13246366 · Cited by 34
“This is consistent with the mechanism of action of anti-CTLA-4, as preclinical murine studies previously showed that Tregs represent direct target cells to anti-CTLA-4 therapy due to their CTLA-4 expression [69,70].”
ResultHeckel, F., Turaj, A. H., Fisher, H., Chan, H. T. C., Marshall, M. J. E., Dadas, O., Penfold, C. A., Inzhelevskaya, T., Mockridge, C. I., Alvarado, D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03182-6 · Cited by 33
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 29
“In mouse models, anti-CTLA-4 mediated Treg depletion has been observed, but similar observations have not been reported in clinical applications [86, 87].”
BackgroundWilliams, K. C., Gault, A., Anderson, A. E., Stewart, C. J., Lamb, C. A., Speight, R. A., Rajan, N., Plummer, R., & Pratt, A. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122430 · Cited by 28
“AntiCTLA-4 can deplete intra-tumoral Tregs in mice (47) and antibodydependent cell-mediated cytotoxicity (ADCC)-mediated lysis of Tregs has been proposed as a potential mechanism of irAE development in humans (48).”
BackgroundCaudana, P., Núñez, N. G., Rochère, P. D. L., Pinto, A., Denizeau, J., Alonso, R., Niborski, L. L., Lantz, O. J., Sedlik, C., & Piaggio, E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0697 · Cited by 29
“Given that both NK and Tregs can be boosted by IL2 (26), that CTLA-4 mAb can deplete Tregs (22), and that Tregs suppress NK cells (31, 32), we investigated the impact of the treatments on the NK cell/Treg ratio.”
BackgroundInfluentialType 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
Martinov, T., & Fife, B. T. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14106 · Cited by 31
Bauché, D., Mauze, S., Kochel, C. M., Grein, J., Sawant, A., Zybina, Y., Blumenschein, W. M., Yang, P., Annamalai, L., Yearley, J. H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001584 · Cited by 29
TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
Msaouel, P., Genovese, G., Gao, J., Sen, S., & Tannir, N. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1869212 · Cited by 28
Krebs, F. K., Trzeciak, E. R., Zimmer, S., Özistanbullu, D., Mitzel-Rink, H., Meißner, M., Grabbe, S., Loquai, C., & Tuettenberg, A. (2021) · Cancer Medicine · doi:10.1002/cam4.3710 · Cited by 28
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 27
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 40
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Page, D. B., Bourla, A. B., Daniyan, A. F., Naidoo, J., Smith, E. L., Smith, M. M., Friedman, C. F., Khalil, D. N., Funt, S. A., Shoushtari, A. N., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0072-2 · Cited by 28
Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer
Li, T., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188384 · Cited by 27
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
Sznol, M., & Melero, I. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.018 · Cited by 29
Nanotechnology synergized immunoengineering for cancer
Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 28
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
Walsh, M. J., & Dougan, M. L. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101473 · Cited by 29
FcγRIIB as a Key Determinant of Agonistic Antibody Efficacy
White, A. L., Beers, S. A., & Cragg, M. S. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_16 · Cited by 28
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Mata, J. J., Rebollo-Liceaga, J., Martinez-Navarro, E., Manzano, R. G., Brugarolas, A., Juan, M., & Sureda, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926289 · Cited by 28
Hartmann, L., Osen, W., Eichmüller, O. L., Kordaß, T., Furkel, J., Dickes, E., Reid, C., Debus, J., Brons, S., Abdollahi, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215928 · Cited by 27
Significance of regulatory T cells in cancer immunology and immunotherapy
Sugiyama, D., Hinohara, K., & Nishikawa, H. (2022) · Experimental Dermatology · doi:10.1111/exd.14721 · Cited by 27
Targeting the Alternatively Spliced Soluble Isoform of CTLA-4: Prospects for Immunotherapy?
Ward, F. J., Dahal, L. N., Khanolkar, R. C., Shankar, S. P., & Barker, R. N. (2014) · Immunotherapy · doi:10.2217/imt.14.73 · Cited by 28
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy
Reardon, D. A., Gilbert, M. R., Wick, W., & Liau, L. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov178 · Cited by 30
Bachran, C., Schröder, M., Conrad, L., Cragnolini, J. J., Tafesse, F., Helming, L., Ploegh, H. L., & Swee, L. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-17948-0 · Cited by 32
Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity
Schrand, B., Clark, E., Levay, A. K., Rabasa, A., Martínez, O., Brenneman, R., Castro, I., & Gilboa, E. (2018) · Nature Communications · doi:10.1038/s41467-018-05566-x · Cited by 27
Bicak, M., Lückerath, K., Kalidindi, T. M., Phelps, M. E., Strand, S., Morris, M. J., Radu, C. G., Damoiseaux, R. D., Peltola, M. T., Peekhaus, N. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918744117 · Cited by 27
“However, the therapeutic action is also an effect of the capacity of the mAb to activate FcγR-expressing macrophages within the tumor microenvironment (32).”
BackgroundRossi, A. H., Farias, A., Fernández, J. E., Bonomi, H. R., Goldbaum, F. A., & Berguer, P. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126827 · Cited by 30
Jenkins, K. A., Park, M., Pederzoli-Ribeil, M., Eskiocak, U., Johnson, P. M., Guzman, W., McLaughlin, M., Moore-Lai, D., O’Toole, C., Liu, Z., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007785 · Cited by 28
“13 14 In vitro studies have shown a correlation between anti- CTLA-4 mAb affinity for Fc γ RIII and ADCC activity induced by the anti- CTLA-4 mAb.”
BackgroundPost-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
Mok, S., Çobanoğlu, D. A., Liu, H., Mancuso, J. J., & Allison, J. P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404661121 · Cited by 28
“Additionally, while anti - CTLA - 4 (clone 9H10) has the Fc chain necessary for antibody - dependent cellular cytotoxicity (ADCC) for Treg depletion, its effect is observable only within tumors and not in the spleen and lymph nodes (22).”
Self-citationThe Problem with Syngeneic Mouse Tumor Models
Lönberg, N. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1046 · Cited by 27
Macrophages at the crossroads of anticancer strategies
Marchesi, F. (2019) · Frontiers in bioscience · doi:10.2741/4779 · Cited by 27
Gordan, S., Albert, H., Danzer, H., Lux, A., Biburger, M., & Nimmerjahn, F. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.111 · Cited by 26
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.